中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

48 records (took 0.092 seconds)

    CARRIER FOR TARGETING NERVE CELLS
    33.
    发明申请
    CARRIER FOR TARGETING NERVE CELLS 有权
    携带神经细胞

    公开(公告)号：US20150038401A1

    公开(公告)日：2015-02-05

    申请号：US14451984

    申请日：2014-08-05

    Applicant: SYNTAXIN LIMITED

    Inventor： Andreas Rummel ,  Tanja Weil ,  Aleksandrs Gutcaits

    IPC: C12N9/52 ,  C07K14/33

    CPC classification number: C12N9/52 ,  A61K38/00 ,  C07K14/33 ,  C12Y304/24069 ,  Y02A50/469 ,  Y02A50/473

    Abstract: The present invention relates to a transport protein which can be obtained by modifying the heavy chain of the neurotoxin formed by Clostridium botulinum wherein (i) the protein binds specifically to nerve cells with a higher or lower affinity as the native neurotoxin; (ii) the protein has an increased or reduced neurotoxicity compared to the native neurotoxin, the neurotoxicity being preferably determined in the hemidiaphragm assay; and/or (iii) the protein comprises a lower affinity against neutralizing antibodies compared to the native neurotoxin. The invention also relates to methods for producing the same and the use thereof in cosmetic and pharmaceutical compositions.

    Abstract translation: 本发明涉及通过改变由肉毒梭菌形成的神经毒素的重链而获得的转运蛋白，其中（i）所述蛋白质以与天然神经毒素更高或更低的亲和力的神经细胞特异性结合; （ii）与天然神经毒素相比，蛋白质具有增加或减少的神经毒性，神经毒性优选在膈膜测定中确定; 和/或（iii）与天然神经毒素相比，蛋白质包含对中和抗体的较低亲和力。 本发明还涉及其制备方法及其在化妆品和药物组合物中的用途。

    SUPPRESSION OF NEUROENDOCRINE DISEASES
    34.
    发明申请
    SUPPRESSION OF NEUROENDOCRINE DISEASES 审中-公开
    抑制神经退行性疾病

    公开(公告)号：US20140302006A1

    公开(公告)日：2014-10-09

    申请号：US14250959

    申请日：2014-04-11

    Applicant: Syntaxin Limited

    Inventor： Steven JOHNSTONE ,  Philip MARKS ,  Keith FOSTER

    IPC: C12N9/52

    CPC classification number: C12N9/52 ,  A61K38/00 ,  C07K2319/035 ,  C07K2319/06 ,  C12P21/06

    Abstract: The present invention relates to a method for suppressing neuroendocrine disease. The therapy employs use of a non-cytotoxic protease, which is targeted to a neuroendocrine tumour cell, preferably via a somatostatin or cortistatin receptor, a GHRH receptor, a ghrelin receptor, a bombesin receptor, a urotensin receptor a melanin-concentrating hormone receptor 1; a KiSS-1 receptor or a prolactin-releasing peptide receptor. When so delivered, the protease is internalised and inhibits secretion from said tumour cell. The present invention also relates to polypeptides and nucleic acids for use in said methods.

    Abstract translation: 本发明涉及抑制神经内分泌疾病的方法。 该疗法使用非细胞毒性蛋白酶，其优选靶向神经内分泌肿瘤细胞，优选经由生长抑素或皮质抑素受体，GHRH受体，生长素释放肽受体，铃蟾肽受体，泌尿生素受体，黑色素浓缩激素受体1 ; KiSS-1受体或催乳素释放肽受体。 当这样传递时，蛋白酶被内化并且抑制来自所述肿瘤细胞的分泌。 本发明还涉及用于所述方法的多肽和核酸。

    SUPPRESSION OF CANCERS
    35.
    发明申请
    SUPPRESSION OF CANCERS 审中-公开
    抑制癌症

    公开(公告)号：US20140219983A1

    公开(公告)日：2014-08-07

    申请号：US14250954

    申请日：2014-04-11

    Applicant: Syntaxin Limited

    Inventor： Frederic MADEC ,  Phil LECANE ,  Philip MARKS ,  Keith FOSTER

    IPC: C12N9/50 ,  C07K14/60 ,  C07K14/33 ,  C07K14/82 ,  C07K7/08 ,  C07K14/48 ,  C07K14/575 ,  C07K14/65

    Abstract: The present invention relates to a method for suppressing or treating cancer, in particular to a method for suppressing or treating one or more of colorectal cancer, breast cancer, prostate cancer and/or lung cancer. The therapy employs use of a non-cytotoxic protease, which is targeted to a growth hormone-secreting cell such as to a pituitary cell. When so delivered, the protease is internalised and inhibits secretion/transmission of growth hormone from said cell. The present invention also relates to polypeptides and nucleic acids for use in said methods.

    Abstract translation: 本发明涉及抑制或治疗癌症的方法，特别涉及抑制或治疗结肠直肠癌，乳腺癌，前列腺癌和/或肺癌中的一种或多种的方法。 该疗法使用非细胞毒性蛋白酶，其靶向生长激素分泌细胞，例如垂体细胞。 当这样传递时，蛋白酶被内化并且抑制生长激素从所述细胞的分泌/传递。 本发明还涉及用于所述方法的多肽和核酸。

    FUSION PROTEINS
    37.
    发明申请
    FUSION PROTEINS 审中-公开
    融合蛋白

    公开(公告)号：US20140056870A1

    公开(公告)日：2014-02-27

    申请号：US13595927

    申请日：2012-08-27

    Applicant: Peter James ,  Keith Foster ,  John Chaddock ,  Kei Roger Aoki ,  Lance Steward ,  Joseph Francis

    Inventor： Peter James ,  Keith Foster ,  John Chaddock ,  Kei Roger Aoki ,  Lance Steward ,  Joseph Francis

    IPC: C12N9/48 ,  A61P29/00 ,  A61K38/48 ,  C12N15/57 ,  C12N15/63

    Abstract: A single chain, polypeptide fusion protein, comprising: a non-cytotoxic protease, which cleaves a protein of the exocytic fusion apparatus of a nociceptive sensory afferent; a galanin Targeting Moiety that binds a Binding Site on the nociceptive sensory afferent, which can undergo endocytosis to be incorporated into an endosome; a protease cleavage site where the fusion protein is cleavable by a protease located between the non-cytotoxic protease and the galanin Targeting Moiety; a translocation domain that translocates the protease from within an endosome, across the endosomal membrane and into the cytosol of the nociceptive sensory afferent; a first spacer from 4 to 25 amino acids between the non-cytotoxic protease and protease cleavage site; and a second spacer comprising from 4 to 35 residues between the galanin Targeting Moiety and translocation domain. Nucleic acid sequences encoding the polypeptide fusion proteins, methods of preparing same and uses thereof are also described.

    Abstract translation: 一种单链多肽融合蛋白，其包含：非细胞毒性蛋白酶，其切割伤害性感觉传入的胞外融合装置的蛋白质; 将甘露聚糖靶向部位结合到伤害性感觉传入物上的结合位点，其可能经历内吞作用以掺入内体; 蛋白酶切割位点，其中融合蛋白可被位于非细胞毒性蛋白酶和甘丙肽靶向部位之间的蛋白酶切割; 一个易位结构域，其从内体内转移蛋白酶，穿过内体膜并进入伤害性感觉传入体的细胞溶质; 非细胞毒性蛋白酶和蛋白酶切割位点之间的4至25个氨基酸的第一个间隔区; 以及在甘露糖靶向部位和易位结构域之间包含4至35个残基的第二间隔物。 还描述了编码多肽融合蛋白的核酸序列，其制备方法及其用途。

    Non-cytotoxic fusion proteins comprising EGF muteins
    38.
    发明授权
    Non-cytotoxic fusion proteins comprising EGF muteins 有权
    包含EGF突变蛋白的非细胞毒性融合蛋白

    公开(公告)号：US08614069B2

    公开(公告)日：2013-12-24

    申请号：US13059695

    申请日：2009-08-19

    Applicant: Aimee Cossins ,  Ian Birch-Machin ,  Patrick Stancombe

    Inventor： Aimee Cossins ,  Ian Birch-Machin ,  Patrick Stancombe

    IPC: C12P21/04

    CPC classification number: C07K14/485 ,  A61K38/00 ,  C07K2319/01 ,  C07K2319/50

    Abstract: The present invention relates to fusion proteins comprising a non-cytotoxic protease and a EGF mutein ligand. The EGF mutein provides improved EGF receptor activation for the claimed fusion proteins. Also provided is the use of said polypeptides as therapeutics for suppressing mucus hypersecretion, inflammation, endocrine neoplasia and/or neuroendocrine disorders, neuroendocrine tumors, for suppressing cancers such as colorectal cancer, prostate cancer, breast cancer, and lung cancer.

    Abstract translation: 本发明涉及包含非细胞毒性蛋白酶和EGF突变蛋白配体的融合蛋白。 EGF突变蛋白为所要求的融合蛋白提供改善的EGF受体活化。 还提供了所述多肽作为抑制粘液分泌过多，炎症，内分泌瘤形成和/或神经内分泌障碍，神经内分泌肿瘤，用于抑制癌症如结肠直肠癌，前列腺癌，乳腺癌和肺癌的治疗剂的用途。

    METHOD OF PREPARING A FUSION PROTEIN FOR THE INHIBITION OR REDUCTION OF SECRETION OF AN EXTRACELLULAR MEDIATOR FROM A TARGET CELL
    40.
    发明申请
    METHOD OF PREPARING A FUSION PROTEIN FOR THE INHIBITION OR REDUCTION OF SECRETION OF AN EXTRACELLULAR MEDIATOR FROM A TARGET CELL 审中-公开
    用于抑制或减少来自目标细胞的细胞外介质分泌的融合蛋白的方法

    公开(公告)号：US20130122526A1

    公开(公告)日：2013-05-16

    申请号：US13528762

    申请日：2012-06-20

    Applicant: Keith Foster ,  John Chaddock ,  Charles Penn

    Inventor： Keith Foster ,  John Chaddock ,  Charles Penn

    IPC: C12N9/52

    CPC classification number: C12N9/52 ,  A61K47/64 ,  A61K47/642

    Abstract: The present invention provides a method for designing a re-targeted toxin conjugate for use in treating a medical condition or disease. Also provided, is the use of said conjugates in the manufacture of a medicament for treating medical conditions or diseases. The conjugates include a Targeting Moiety, which directs the conjugate to a desired target cell, and are characterised by a Targeting Moiety that increases exocytic fusion in the target cell. The present invention also provides methods for identifying agonists suitable for use as Targeting Moieties, and methods for preparing conjugates comprising said Targeting Moieties.

    Abstract translation: 本发明提供了一种用于设计用于治疗医学病症或疾病的再靶向毒素缀合物的方法。 还提供了所述缀合物在制备用于治疗医学病症或疾病的药物中的用途。 缀合物包括将缀合物引导至期望的靶细胞的靶向部位，其特征在于靶细胞增加靶细胞中的胞外融合。 本发明还提供了用于鉴定适合用作靶向部分的激动剂的方法，以及制备包含所述靶向部分的缀合物的方法。

Patent Agency Ranking